OPEN END TURBO LONG - ASTRAZENECA | Real-time Bid/Ask 11:28:22 03/06/2024 BST | ||
| 0.7 EUR / 0.71 EUR | +17.50% |
|
| 1 month | -25.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.6 | +9.09% |
| 30/05/24 | 0.55 | +10.00% |
| 29/05/24 | 0.5 | -28.57% |
| 28/05/24 | 0.7 | -16.67% |
| 24/05/24 | 0.84 | -16.00% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 11:09 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MG37WB |
| ISIN | DE000MG37WB1 |
| Date issued | 29/04/2024 |
| Strike | 11,615 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.62 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.06 € |
|---|---|
| Lowest since issue | 0.5 € |
| Spread | 0.01 € |
| Spread % | 1.45% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.91%
- Stock Market
- Certificates
- Certificat
